Elias Kassab, MD Notes DABRA Laser System Successful for Treating Challenging Lesions

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

May 30, 2020

Elias Kassab, MD, presented his successful experience using the DABRA laser system. “We have found that DABRA is successful in treating challenging lesions including long and severely calcified lesions, both above and below the knee.” The presentation was delivered on Wednesday, May 29, 2019, at the annual New Cardiovascular Horizons (NCVH) conference in New Orleans.

Elias Kassab, MD, FACC, FSCAI, FACP. FASA, RPVI, FAHA, FSVM, President & CEO of Michigan Outpatient Vascular Institute, Dearborn, Michigan said, “The device has an innate tendency to stay intraluminal in all vessels, is versatile as a single debulking device, is easy to use and is cost-effective.” He added, “In our experience, DABRA has a very low complication rate and we have not seen any angiographic or clinical evidence of distal embolization.”

Dr. Kassab and Ashok Kondur, MD, recently reported that DABRA achieved a 98% lesion success rate in a 52-patient, single-center study that was summarized in the 2019 LINC Review. “Although these findings are from just 52 patients, they are very promising and strengthen the case for more extensive study of DABRA,” said Dr. Kassab.

DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) is a novel, minimally invasive excimer laser system that non-thermally and photochemically ablates channels in vascular blockages. The technology reduces all plaque types into their fundamental chemistry, such as proteins, lipids, and other chemical compounds, eliminating blockages by dissolving them without generating potentially harmful particulates. Unlike many mechanical, acoustic, or thermal treatments for peripheral artery disease (PAD) that may damage the arterial wall, DABRA treats blockages with minimal vascular trauma.

DABRA quickly, safely, and efficiently restores blood flow, often in very difficult cases, enabling physicians to save patients’ limbs and lives,” added Dean Irwin, CEO, Ra Medical Systems.



Subscribe to Medical Device News Magazine

Related Articles